Volatile anesthetic agents have been used for decades in the peri-operative setting. Data from the past 15 years have shown that pre-injury administration of volatile anesthetic can decrease the impact of ischemia-reperfusion injury on the heart, brain, and kidney. Recent data demonstrated that volatile agents administered shortly after injury can decrease the ischemia-reperfusion injury. Several questions need to be answered to optimize this therapeutic target, but this is a promising era of secondary injury mitigation.
Cardiac anesthesia is associated with ischemia-reperfusion injury. Trying to limit the extent and mitigate the consequences of ischemia could potentially improve outcome after cardiac surgery. In the last 10 to 15 years, volatile agents have been shown to improve outcome in cardiac surgery. Despite these data, volatile anesthesia is not the most widely used technique for cardiac anesthesia. In the previous issue of Critical Care, Steurer and colleagues [1] presented interesting data on sevofl urane administration following cardiac surgery. Th ese data have to be placed in the context of already-accumulated evidence and potential clinical applications.
Anesthetic gases are fascinating drugs: First-generation anesthetic gases, especially halothane, had signifi cant cardiac side eff ects, increasing the risk of malignant arrhythmia and sensitizing the heart to catecholamines. Further generations, especially sevofl urane, have been shown to have interesting neuro-and cardioprotective properties. In the last 10 to 15 years, a wealth of data has shown that peri-operative administration of halogenated agents is associated with myocardial protection and better outcome.
Darwin proposed that species adapt to environment, the better-adapted breed having the better chances of survival. Interestingly, at the tissue, cell, mitochondrion, and possibly the gene level, there is a dynamic adaptation to the environment. Th is led to the concept of preconditioning, a mechanism in which brief sublethal periods of ischemia will provide protection from a subsequent lethal ischemia and mitigate the eff ect of ischemia-reperfusion [2] . As stated by Friedrich Nietzsche, 'What does not destroy me, makes me stronger' . Th e organism or the tissue will acquire some 'injury-resistant' phenotype for a certain period of time [3] . Ischemic pre-conditioning is an interesting and powerful concept, but its clinical applicability is limited by the already-jeopardized myocardium.
All hypnotics decrease myocardial consumption and may favor the myocardial oxygen supply/demand balance. On top of these macrohemodynamic eff ects, halogenated agents have intrinsic cardio-and neuroprotective eff ects that are similar to those of ischemic pre-conditioning. At a basic science level, the myocardial protection eff ects of sevofl urane involve apoptotic mRNA inhibition, neuromodulation, cytokine/infl amma tion modulation, redoxsensitive path ways, endothelial preservation, ion channels, notch signal ing pathways, and probably other mechanisms to be discovered. Th is translates clinically as a decrease in post-cardiac surgery troponin levels, lower inotropes requirements, and better cardiac output. Precondition ing is well established, and volatile agents are now recommended as the agent of choice by the American Heart Association for high-risk patients [4] .
However, pre-conditioning is diffi cult to apply once the injury has already been established. Interestingly, brief periods of ischemia at the onset of the reperfusion period are associated with cardioprotection, leading to a myocardial infarction size decrease similar to [5] or slightly inferior to that of ischemic pre-conditioning [6] . Iso fl urane has been shown to improve remodeling after coronary artery occlusion in rats [7] . In a similarly designed animal model of circulatory arrest published last year in this journal, sevofl urane administered immediately after the return of spontaneous circulation decreased myocardial damage [8] . Th e mechanisms of volatile agent postconditioning are being explored by several laboratories around the world [9, 10] . Lemoine and colleagues [11] showed on in vitro right atrial appendages that the human heart is sensitive to desfl urane-associated postconditioning. Th e data from Steurer and colleagues [1] off er the 'fi rst in man' evidence of post-conditioning and potential myocardial protection in a clinical setting: sevofl urane administered in the intensive care unit (ICU) arrival for 4 hours. Th ey showed a decreased troponin release in the sevofl urane group. Interestingly, there was still an eff ect even with a 2-to 3-hour gap after the onset of ischemia (aortic clamping) and a 1-to 2-hour gap between the start of reperfusion (aortic cross-clamp release) and the administration of sevofl urane (upon arrival to the ICU). Th is investigation opens a new fi eld and new potential therapeutic opportunities. Further questions remain to be answered to optimize and assess the clinical magnitude of myocardial protection provided by post-conditioning (Table 1) .
Sevofl urane and isofl urane are very fl exible generic anesthetic drugs administered daily by numerous anesthetists around the world. Th e demon stration of cardioor neuroprotective eff ects (or both) when applied after the ischemia will make them interesting in myocardial ischemia, cardiogenic shock, or even traumatic brain injuries. Sevofl urane administration in the ICU has been done previously [12, 13] . It has been shown to be associated with fast awakening/weaning times after the drug is stopped [12] . Th e anesthesia-conserving device has made the delivery simple and adaptable on 'regular' ICU-type ventilators. However, technical aspects such as gas analyzers, concentration measurement, and exhausted gas scavenging (most ICU-type ventilators release the exhaust gases into the environment) need to be taken into account. Educational aspects must include nurse training, dosage, availability of dantrolene, and training for the unlikely event of a malignant hyperthermia reaction. In addition, data show plasma fl uoride concentration (39 ± 25 μmol/L) close to safety limits (50 μmol/L) at 24 and 48 hours after 9 hours of sevofl urane [14] . Sevofl urane administration beyond 12 to 24 hours needs to be assessed in terms of fl uoride plasma concentration and nephrotoxicity. Environmental eff ects of widespread anesthetic gas use need to be taken into account [15] . Most cardiac surgery patients require a maximum of a few hours of mechanical ventilation (if any). In these circumstances, sevofl urane sedation in the cardiac ICU may be a very fl exible option with an additional myocardial protection benefi t.
Conclusions
Sevofl urane and possibly other volatile anesthetic agents show promising post-conditioning properties after cardiac surgery. Th is opens a new fi eld of investigations and potential therapies aiming at mitigating secondary myocardial injury after the primary injury is done. More data are necessary to assess the magnitude conferred by this protection, its clinical relevance, the window of opportunity, and the collateral protection on other organs. Very promising answers, and more questions, are to come.
Abbreviation ICU, intensive care unit.
Table 1. Some research questions regarding sevofl urane post-conditioning
Is the post-conditioning eff ect related to the "dose" of sevofl urane? Is there a minimum duration or minimum alveolar concentration to obtain post-conditioning? Is there a dose response curve on sevofl urane post-conditioning? Do all volatile anesthetic agents (isofl urane or desfl urane) provide the same post-conditioning organ protection?
Does the lower release in cardiac damage markers shown by Steurer et al. [1] translate into outcome diff erences? Lower myocardial infarction rates? Lower inotropic support? Better cardiac output? Shorter intensive care unit/hospital stays? Lower mortality? Lower resource utilization?
How long is the therapeutic window after reperfusion to exhibit a post-conditioning organ protection? That is, how long after cardiopulmonary bypass or injury does sevofl urane have to be started to induce post-conditioning?
Is there an additional cardioprotective eff ect when sevofl urane is used intraoperatively (pre-conditioning)?
Is there a protective eff ect on other organs such as the brain or the kidney?
Animal data suggest that post-conditioning is better in males [16] and inhibited by hyperglycemia [17] : Is post-conditioning benefi cial only in males or in the context of tight glucose control (or both)?
Sevofl urane administration is associated with plasma fl uoride levels above upper limit. How long can we use sevofl urane for sedation/post-conditioning in terms of fl uoride toxicity?
